Supplementary Material for: Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression Wilkinson S.T. Wright D. Fasula M.K. Fenton L. Griepp M. Ostroff R.B. Sanacora G. 10.6084/m9.figshare.4990574.v1 https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Cognitive_Behavior_Therapy_May_Sustain_Antidepressant_Effects_of_Intravenous_Ketamine_in_Treatment-Resistant_Depression/4990574 <p><b><i>Introduction:</i></b> Ketamine has shown rapid though short-lived antidepressant effects. The possibility of concerning neurobiological changes following repeated exposure to the drug motivates the development of strategies that obviate or minimize the need for longer-term treatment with ketamine. In this open-label trial, we investigated whether cognitive behavioral therapy (CBT) can sustain or extend ketamine's antidepressant effects. <b><i>Methods:</i></b> Patients who were pursuing ketamine infusion therapy for treatment-resistant depression were invited to participate in the study. If enrolled, the subjects initiated a 12-session, 10-week course of CBT concurrently with a short 4-treatment, 2-week course of intravenous ketamine (0.5 mg/kg infused over 40 min) provided under a standardized clinical protocol. <b><i>Results:</i></b> Sixteen participants initiated the protocol, with 8 (50%) attaining a response to the ketamine and 7 (43.8%) achieving remission during the first 2 weeks of protocol. Among ketamine responders, the relapse rate at the end of the CBT course (8 weeks following the last ketamine exposure) was 25% (2/8). On longer-term follow-up, 5 of 8 subjects eventually relapsed, the median time to relapse being 12 weeks following ketamine exposure. Among ketamine remitters, 3 of 7 retained remission until at least 4 weeks following the last ketamine exposure, with 2 retaining remission through 8 weeks following ketamine exposure. Ketamine nonresponders did not appear to benefit from CBT. <b><i>Conclusions:</i></b> CBT may sustain the antidepressant effects of ketamine in treatment-resistant depression. Well-powered randomized controlled trials are warranted to further investigate this treatment combination as a way to sustain ketamine's antidepressant effects.</p> 2017-05-10 11:36:02 Cognitive behavior therapy Major depressive disorder Relapse Treatment-resistant depression Cognition Ketamine